Candesartan and renal protection: more than blocking angiotensin type 1 receptor?
Chen et al. show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation. The peculiarity of Cand in combining AT1R-blocking activity and an antioxidant action could have important theoretical implications for therapy.